BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including Presbyopia, Cataracts, and Glaucoma

BIOLASE Issued Broad New Patent for Treating Eye Conditions, Including 
Presbyopia, Cataracts, and Glaucoma 
Provides Additional Support for Ophthalmic Applications 
IRVINE, CA -- (Marketwired) -- 05/29/13 --  BIOLASE, Inc. (NASDAQ:
BIOL), the world's leading manufacturer and distributor of dental
lasers, announced today that the U.S. Patent and Trademark Office has
issued BIOLASE a new patent covering the use of its laser
technologies for treating various conditions of the eye, including
presbyopia, cataracts, and glaucoma.  
Patent 8,448,465 is titled "Methods for Treating Eye Conditions," and
significantly broadens the claims for this patent family and
anticipates using complementary technologies to automate and perfect
procedures to identify the rigidity of the eye to optimize treatment
locations in presbyopia procedures. 
Federico Pignatelli, Chairman and Chief Executive Officer, commented,
"This patent extends and reinforces the ability of BIOLASE's wholly
owned subsidiary OCCULASE, Inc. to strategically partner with
companies that offer complimentary technologies that enhance our core
laser technologies. Such strategic affiliations will allow for
greater predictability and more consistent visual outcomes for the
patient. Our revolutionary technology has the ability to reduce the
learning curve for ophthalmologists and decrease the required
surgical time. We will continue to expand our intellectual property
in order to establish OCCULASE as a leader in the ophthalmic laser
arena, not only by developing the best clinical solutions but also
cost effective ones." 
This is the tenth U.S. patent issued under the "Methods for Treating
Eye Conditions" patent family with an additional three patents issued
internationally and six more pending worldwide. BIOLASE currently
holds a total of 20 issued and 20 pending U.S. and international
patents in seven patent families in the field of ophthalmology. These
patents give BIOLASE and its wholly-owned subsidiary, OCCULASE, the
widest range of potential applications and coverage in the field.  
"This patent further leverages our innovative WaterLase technology
and incorporates the ocular rigidity theory which broadens our patent
family to allow the laser parameters and groupings of tissue
treatment to compensate for correlation in the various layers in
ocular tissue for treating eye conditions such as presbyopia,
cataract, and glaucoma, among many others," added Marcia Van Valen,
Director of Business Development. 
"This new patent and those currently under application further
demonstrate how broad the applications are for our patented laser
technologies within ophthalmology," concluded Pignatelli. 
About BIOLASE, Inc.
 BIOLASE, Inc. is a biomedical company that
develops, manufactures, and markets innovative lasers in dentistry
and medicine and also markets and distributes high-end 2D and 3D
digital imaging equipment and CAD/CAM intraoral scanners; products
that are focused on technologies that advance the practice of
dentistry and medicine. The Company's proprietary laser products
incorporate over 350 patented and patent-pending technologies
designed to provide biologically clinically superior performance with
less pain and faster recovery times. Its imaginative products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
revolutionary dental laser systems that perform a broad range of
dental procedures, including cosmetic and complex surgical
applications, and a full line of dental imaging equipment. BIOLASE
has sold more than 22,500 lasers. Other laser products under
development address ophthalmology and other medical and consumer
For updates and information on WaterLase(R) and laser dentistry, find
BIOLASE(R) online at, Facebook at, Twitter at,
Pinterest at, LinkedIn at, Instagram at and YouTube at  
BIOLASE(R) and WaterLase(R) are registered trademarks of BIOLASE,
For further information, please contact: 
Michael Porter 
Porter, LeVay & Rose, Inc. 
Press spacebar to pause and continue. Press esc to stop.